Jacobus Pfisterer Selected Research

Jacobus Pfisterer Research Topics

Disease

48	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 09/2003
34	Neoplasms (Cancer) 12/2023 - 06/2002
14	Carcinoma (Carcinomatosis) 12/2023 - 01/2004
10	Ovarian Epithelial Carcinoma 01/2017 - 03/2006
6	Residual Neoplasm 01/2023 - 10/2004
3	Disease Progression 01/2020 - 08/2015
2	Alopecia (Baldness) 05/2015 - 04/2006
2	Ascites 07/2007 - 12/2006
1	Genomic Instability 02/2022
1	Vulvar Neoplasms (Vulvar Cancer) 12/2020
1	Thrombocytosis (Thrombocythemia) 01/2020
1	Necrosis 01/2020
1	Tertiary Lymphoid Structures 01/2018
1	Immune System Diseases (Immune Disorders) 01/2018
1	Endometrial Neoplasms (Endometrial Cancer) 03/2016
1	Renal Insufficiency (Renal Failure) 01/2016
1	Sepsis (Septicemia) 01/2016
1	Peritonitis 01/2016
1	Neutropenia 01/2016
1	Thrombocytopenia (Thrombopenia) 01/2016
1	Fistula 08/2015
1	Heart Failure 08/2015
1	Sarcoidosis (Schaumann Disease) 08/2015
1	Body Weight (Weight, Body) 12/2011
1	Hypertension (High Blood Pressure) 12/2011
1	Venous Thromboembolism 06/2008
1	Neoplasm Metastasis (Metastasis) 01/2008
1	Endometrioid Carcinoma 01/2008
1	Adenocarcinoma 01/2008
1	Fallopian Tube Neoplasms 04/2007
1	Diarrhea 04/2007
1	Papillary Carcinoma 01/2007
1	Transitional Cell Carcinoma 04/2005
1	Squamous Cell Carcinoma of Head and Neck 06/2004
1	Onycholysis 06/2002

Drug/Important Bio-Agent (IBA)

20	PlatinumIBA 01/2020 - 04/2005
19	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 09/2003
18	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 09/2003
10	Bevacizumab (Avastin)FDA Link 12/2023 - 12/2011
10	taxaneIBA 01/2019 - 04/2006
5	AntigensIBA 01/2019 - 06/2004
4	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2007
4	Gemcitabine FDA Link 01/2020 - 04/2006
4	abagovomabIBA 04/2013 - 01/2010
4	Cisplatin (Platino)FDA LinkGeneric 10/2006 - 09/2003
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2007
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2023 - 01/2022
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2022 - 01/2018
2	nintedanibIBA 02/2022 - 01/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2008
2	Hematoxylin (Haematoxylon)IBA 11/2015 - 03/2009
2	Eosine Yellowish-(YS) (Eosin)IBA 11/2015 - 03/2009
2	VaccinesIBA 01/2010 - 06/2004
2	Topotecan (Hycamtin)FDA LinkGeneric 08/2009 - 08/2006
1	Fibroblast Growth Factor 1 (FGF-1)IBA 12/2023
1	LigandsIBA 12/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2023
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 12/2023
1	Protein Isoforms (Isoforms)IBA 11/2022
1	Immune Checkpoint InhibitorsIBA 02/2022
1	ChromatinIBA 01/2021
1	liposomal doxorubicin (Doxil)FDA Link 01/2020
1	thiaclopridIBA 01/2019
1	AutoantigensIBA 01/2018
1	anti-Yo autoantibodiesIBA 01/2018
1	temsirolimus FDA Link 03/2016
1	Tumor Biomarkers (Tumor Markers)IBA 09/2015
1	CA-125 Antigen (CA 125 Antigen)IBA 02/2011
1	treosulfanIBA 08/2009
1	Alkylating AgentsIBA 08/2009
1	Biological FactorsIBA 03/2009
1	human ERBB2 proteinIBA 01/2009
1	catumaxomabIBA 07/2007
1	Epithelial Cell Adhesion MoleculeIBA 07/2007
1	Gefitinib (Iressa)FDA Link 04/2007
1	Tamoxifen FDA LinkGeneric 04/2007
1	Matrix Metalloproteinase 7 (Matrilysin)IBA 01/2007
1	OligonucleotidesIBA 01/2007
1	Secretory Leukocyte Peptidase InhibitorIBA 01/2007
1	Kallikreins (Kallikrein)IBA 01/2007
1	OsteopontinIBA 01/2007
1	vasectrin IIIIBA 12/2006
1	Indicators and Reagents (Reagents)IBA 10/2006
1	Epirubicin (Ellence)FDA LinkGeneric 03/2006
1	HLA-DR Antigens (HLA-DR)IBA 06/2004
1	Fluorescein-5-isothiocyanate (FITC)IBA 06/2004

Therapy/Procedure

29	Drug Therapy (Chemotherapy) 01/2023 - 06/2002
22	Therapeutics 01/2023 - 01/2004
3	Cytoreduction Surgical Procedures 01/2023 - 12/2006
3	Lymph Node Excision (Lymph Node Dissection) 12/2020 - 04/2010
3	Immunotherapy 07/2007 - 03/2004
2	Combination Drug Therapy (Combination Chemotherapy) 01/2010 - 04/2006
1	Duration of Therapy 01/2023
1	Art Therapy 01/2020
1	Precision Medicine 01/2018
1	Operative Surgical Procedures 03/2013
1	Neoadjuvant Therapy 02/2012
1	Drug Tapering 04/2007
1	Time-to-Treatment 03/2006
1	TP protocol 02/2006